Tenax Therapeutics reports Q4 EPS (18c), consensus (43c)

Reports Tenax Therapeutics (TENX) reported cash and cash equivalents of $94.9 M as of December 31 . In addition, in March 2025 the Company raised approximately $25M in gross proceeds from a private placement financing. With the proceeds from the March offering, management believes that Tenax is now funded through 2027. “The past year has been transformational for Tenax Therapeutics in our quest to advance TNX-103, our oral levosimendan drug candidate, and bring meaningful clinical benefit to patients suffering from PH-HFpEF. With the continued support of investors, we are now well-positioned to expand our investment in TNX-103 and accelerate development timelines, paving the way for an earlier potential regulatory filing,” said Chris Giordano, President and Chief Executive Officer of Tenax Therapeutics. “We remain committed to a lean cost structure and responsible capital stewardship, ensuring our current funding sustains Tenax well beyond topline LEVEL data readout. We believe TNX-103 has the potential to improve the quality of life of patients living with PH-HFpEF, and expect to share topline data from LEVEL in the middle of 2026.”